Specifically, CD103+ cDC1s have been identified as playing a crucial role in T cell activation and enhancing anti-tumor immune responses, particularly when combined with ICIs, exhibiting notable effectiveness against osteosarcoma (Zhou et al., 2020b). The gene discussed is ITGAE; the disease is neoplasm.